ClinicalTrials.gg
RecruitingNCT06829784Updated Aug 19, 2026

TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection

A Phase 3 interventional study of TQC2731 injection and Placebo in Asthma, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Recruiting at 101 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
26th of 182
660 · median 203
Started
2025
with 31 others
Phase 3
47 of 251
13 open now
Primary completion
2027-12
later than 64 of 95 live
Registered
197th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 26th largest by planned enrollment of the 182 interventional ones that give a count, is one of 32 that started in 2025, is one of 47 in phase 3, reaches primary completion later than 64 of the 95 other live ones, and was the 197th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of TQC2731 injection (420 mg Q4W) in adult subjects with inadequately controlled severe asthma. A total of 660 trial participants are expected to be enrolled, with trial participants randomized in a 1:1 ratio to receive either TQC2731 (420 mg Q4W) or placebo (Q4W) via subcutaneous (SC) administration.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the form before the trial to fully understand the purpose, process and possible adverse reactions of the trial;
  • Age 18 \~ 75 years old, gender is not limited;
  • Documented physician diagnosis of asthma at least 12 months prior to Visit 1;
  • Subjects who received high-dose Inhaled (ICS) in asthma control medications prescribed by their physicians at least 6 months prior to Visit 1;
  • There must be a record of receiving a stable total daily dose of ICS at least 3 months prior to visit 1;
  • There must be a record of the use of other asthma control medications at a stable dose at least 3 months prior to visit 1; For subjects taking maintenance oral hormones, the dose of oral hormones is up to 10mg prednisone per day or 20mg every other day (or equivalent) and must be stable for at least 30 days prior to visit 1 and during treatment.
  • Documented at least 2 asthma exacerbations in the 12 months prior to Visit 1 and no major asthma exacerbation events in the 1 month prior to signing informed.

Exclusion criteria

Exclusion Criteria:

  • Have a lung disease other than asthma;
  • Pre-existing disease;
  • A history of known or suspected , including a history of invasive opportunistic infections;
  • Any disease that has not been determined to be stable by the investigator;
  • Cancer history: Patients with basal cell carcinoma, skin localized squamous cell carcinoma, or cervical carcinoma in situ are eligible to be enrolled in this study if they had completed curative therapy for at least 12 months prior to visit 1. Patients with other who had completed curative treatment for at least 5 years prior to visit 1 could be enrolled in the study.
  • Current smoker or smoking history ≥10 pack-years (former smokers with smoking history \<10 pack-years had quit smoking less than 6 months before interview 1);
  • Other factors determined by the investigator that subjects were not suitable to participate in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
660 participants (estimated)

Study arms

  • Experimental
    TQC2731 injection

    TQC2731 injection, 4 weeks as a treatment cycle. Study drug administration from Day 0 up to Week 48.

    Drug: TQC2731 injection

  • Placebo comparator
    Placebo

    Placebo,4 weeks as a treatment cycle.Study drug administration from Day 0 up to Week 48.

    Drug: Placebo

Interventions

  • TQC2731 injection can specifically bind to the Thymic Stromal Lymphopoietin (TSLP) protein, blocking TSLP-dependent downstream signaling expression in engineered cells and inhibiting the production of inflammatory cytokines.

  • DrugPlacebo

    Placebo without drug substance.

06

What researchers measure

Primary outcomes

  1. Annualized incidence of asthma exacerbations

    Annualized incidence of asthma exacerbations (AAER) during the 52-week treatment period.

    Time frame: From the first day of dosing to the completion of 52 weeks of treatment

Secondary outcomes

  1. The change in forced expiratory volume in 1 second (FEV1)

    At Week 52, the change from baseline in forced expiratory volume in 1 second (FEV1) prior to dosing and before the use of a bronchodilator (pre-BD administration).

    Time frame: Week 52 before dosing and before the use of bronchodilators (pre-Bronchodilator (pre-BD) administration)

  2. Change in total score of standardized asthma quality of life questionnaire

    Change from baseline in standardized asthma quality of life questionnaire (AQLQ(S)+12) total score at week 52. Scores above 5 points indicate a relatively good quality of life, while scores below 3 points suggest a relatively poor quality of life.

    Time frame: From baseline to week 52

  3. Change in Asthma Control Questionnaire-6 (ACQ-6) score

    Mean change from baseline in weekly mean asthma symptom diary score at week 52, , The higher the score, the more severe the asthma symptoms.

    Time frame: From baseline to week 52

  4. Mean change in weekly mean asthma symptom diary score

    Mean change from baseline in weekly mean asthma symptom diary score at week 52

    Time frame: From baseline to week 52

  5. Change in European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire score

    Change from baseline in European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire score at Week 52, a higher score indicates a better quality of life.

    Time frame: From baseline to week 52

  6. Change in mean rescue medication use, average peak expiratory flow rate (PEF) in the morning and night

    Change from baseline in the average weekly dose of rescue medication and the average peak expiratory flow rate (PEF) per week in the morning and night, respectively

    Time frame: From baseline to week 52

  7. Changes in exhaled nitric oxide Fractional exhaled nitric oxide (FENO) (ppb), peripheral blood eosinophils, total serum Immunoglobulin E (IgE).

    Change from baseline in exhaled nitric oxide FENO (ppb) at week 52.

    Time frame: From baseline to week 52

  8. Changes in peripheral blood eosinophils

    Change from baseline in peripheral blood eosinophils at week 52.

    Time frame: From baseline to week 52

  9. Changes in total serum IgE

    Change from baseline in total serum IgE at week 52.

    Time frame: From baseline to week 52

  10. Time to first asthma exacerbation

    Time to first asthma exacerbation

    Time frame: Baseline to week 64

  11. Proportion of subjects with ≥1 asthma exacerbation

    Proportion of subjects with ≥1 asthma exacerbation

    Time frame: Baseline to week 64

  12. Number of days of glucocorticoid use due to acute exacerbations

    Number of days of glucocorticoid use due to acute exacerbations

    Time frame: Baseline to week 64

  13. Average amount of hormone used per acute exacerbation (prednisone equivalent)

    Average amount of hormone used per acute exacerbation (prednisone equivalent)

    Time frame: Baseline to week 64

  14. Incidence of anti-drug antibodies (ADAs) in subjects

    Immunogenicity: Incidence of anti-drug antibodies (ADAs) in subjects and their titers.

    Time frame: Baseline to week 64

  15. Incidence of neutralizing antibodies(NAB) in subjects

    Immunogenicity: Incidence of neutralizing antibodies (NAB).

    Time frame: Baseline to week 64

07

Study locations

2 of 101 sites recruiting

Showing the first 100 of 101 sites. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 33 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 17, 2025
StartActual
Mar 21, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Mar 2028
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06829784
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Mar 21, 2025
Primary completion
Dec 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Aug 19, 2026

Study contacts

Jinping Zheng, Doctor
Contact
jpzhenggy@163.com
18928868238
Qingling Zhang, Doctor
Contact
zqling68@hotmail.com
13609068871

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC2731

Start the discussion